N/A
N=281
Oral Cell DNA Adducts in Smokers
Lung Cancer
Bottom Line
View on ClinicalTrials.gov: NCT03285893 ↗Enrolled (actual)
281
Serious AEs
—
Results posted
Nov 2024
Primary outcome: Primary: Concentration of γ-OH-Acr-dGuo, a Major Acrolein-DNA Adduct — 49.7; 67.1; 46.5 10^9 nucleotides/mL
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- oral cell DNA adducts (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Minnesota
- Primary completion
- Aug 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Concentration of γ-OH-Acr-dGuo, a Major Acrolein-DNA Adduct |
49.7; 67.1; 46.5 | — |
| SECONDARY εdAdo, Per 10^9 Nucleotides |
11.3; 11.3; 9.16 | — |
Summary
DNA adducts in the oral mucosa cells of 100 smokers from 3 ethnic groups - Native Hawaiians, Whites, and Japanese Americans with differing risks for lung cancer upon cigarette smoking will be quantified. DNA adducts of tobacco smoke carcinogens will be quantified using both targeted and untargeted approaches.
Eligibility Criteria
Inclusion Criteria
- currently smoke at least 5 cigarettes per day, self-identified Japanese Americans, European Americans, or Native Hawaiians.
Exclusion Criteria
- no current use of other nicotine containing products, no acute or uncontrolled medical or psychiatric conditions, no greater than 14 alcoholic drinks per week, not pregnant, not breastfeeding, not currently taking any medications that affect relevant metabolic enzymes, no active infection.
Data sourced from ClinicalTrials.gov (NCT03285893). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.